Amir Kalali, M.D., serves as vice president and head of the Neuroscience Center of Excellence at Quintiles. In this role, Dr. Kalali is responsible for the enterprise-wide strategy for neuroscience, encompassing drug development and healthcare services. Dr. Kalali joined Quintiles in 1997 and is board certified in psychiatry and neurology. He has been involved in numerous successful drug development programs that have led to new treatments for patients.
Prior to joining Quintiles, Dr. Kalali held a number of central nervous system (CNS) research roles at the University of California, Irvine. During his career, Dr. Kalali has been recognized five times by PharmaVOICE magazine as one of the 100 most inspiring leaders in life sciences. In 2014, he was awarded the PharmaVoice Red Jacket Award in recognition of his career-long contributions to the industry.
Dr. Kalali earned his medical degree from the University of London and completed his psychiatry training at University College and Middlesex School of Medicine, University of London. Dr. Kalali was the founding chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD) and also a founding member of the International Society for CNS Clinical Trials and Methodology (ISCTM). He currently serves as a professor of psychiatry at the University of California, San Diego, is editor of the Innovations in Clinical Neuroscience journal, and the lead editor of the book, “Essential CNS Drug Development.”